UCB - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Alcon AG USD 1.58B 80M 2026-03
Almirall EUR 337.77M 14.83M 2025-12
Amarin USD 143.56M 12.5M 2026-06
argenx SE USD 4.3B 808.71M 2026-03
AstraZeneca USD 4.89B 2.67B 2026-06
Bayer EUR 4.29B 1.44B 2026-06
Genmab DKK 1.5B 18M 2026-06
GlaxoSmithKline GBP 3.44B 292M 2026-03
GRIFOLS EUR 513M 189M 2026-06
Hikma Pharmaceutical USD 217M 19M 2025-12
Lakefront Biotherapeutics EUR 135.95M 69.15M 2026-06
Lonza CHF 719M 188M 2025-12
Merck EUR 2.74B 415M 2026-03
Novartis USD 7.62B 739M 2026-06
Orion EUR 199.3M 38.4M 2026-03
Recordati EUR 391.38M 10.92M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
UCB EUR 1.57B 1.14B 2024-12
Unibail Rodamco EUR 5.29B 668.7M 2024-12